“Shifting sands in cystic fibrosis”: impacts of CFTR modulators on reproductive health in people with cystic fibrosis and challenges related to in utero exposure

Mutation-specific disease modifying drugs such as the triple combination Elexacaftor/Tezacaftor/Ivacaftor (ETI), are associated with significant improvements in physical health. Reproductive health and a pursuit of parenthood are of increased relevance; a dramatic increase in childbirth rates for females with CF has already been observed.